Study to Investigate the Safety Profile of AZD4721 After Single Doses at Different Dose Levels

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions

Safety,Plasma AUC and Cmax, Plasma AUC 0-t, t1/2λz, and Tmax

Interventions

DRUG

AZD4721 Solution

1-9 mg/mL liquid solution

DRUG

AZD4721 Placebo

Liquid solution

DRUG

AZD4721 Suspension

9 mg/g liquid suspension

Trial Locations (1)

Research Site, London